Blood Disorders & Hematology Clinical Trials Update: Week 19, 2026

Published May 8, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase 3 trial is testing new chemotherapy combinations using CPX-351 and gilteritinib for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to find treatments that work better and cause fewer heart-related side effects compared to standard chemotherapy. Patients participating in this study across multiple countries may benefit from improved treatment options for this serious blood cancer.

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

This phase 3 trial is testing a new drug combination of mosunetuzumab and lenalidomide for patients with follicular lymphoma that has returned or not responded to previous treatment. The study aims to improve patient outcomes compared to the current standard combination with rituximab. It is actively recruiting patients who have had at least one prior therapy, offering hope for more effective management of this type of lymphoma.

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

This phase 3 trial is investigating a treatment combining tafasitamab and lenalidomide for adults with diffuse large B-cell lymphoma that has returned or resisted treatment. This option is especially important for patients who cannot undergo high-dose chemotherapy or stem cell transplant. The trial is currently active with results pending, potentially providing a new option for this aggressive lymphoma.

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

This phase 3 study is testing new chemotherapy regimens, including dexamethasone, for children and adolescents with lymphoblastic lymphoma. The aim is to reduce relapses in the brain and improve overall survival rates. With over 600 young patients enrolled internationally, this trial hopes to offer safer and more effective treatments for this childhood cancer.

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

This early-phase trial is testing the drug AZD0305 alone or combined with other anticancer treatments in adults with multiple myeloma, a common blood cancer. If successful, it could lead to new treatment options that might be better tolerated or more effective. The study is currently recruiting across several countries, providing access to novel therapies for patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.